Ultragenyx Pharmaceutical (RARE) Accounts Payables (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Accounts Payables data on file, last reported at $42.0 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $42.0 million, down 11.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $42.0 million (down 11.49% YoY), and the FY2025 annual result was $31.0 million, down 20.51% from the prior year.
• Accounts Payables improved to $42.0 million in Q1 2026 per RARE's latest filing, from $31.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $59.8 million in Q2 2024 and troughed at $23.5 million in Q3 2022.
• A 5-year average of $39.5 million and a median of $40.6 million in 2025 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables surged 152.5% in 2022, then plunged 42.75% in 2025.
• A 5-year view of Accounts Payables shows it stood at $43.3 million in 2022, then fell by 2.68% to $42.1 million in 2023, then fell by 7.39% to $39.0 million in 2024, then slipped by 20.51% to $31.0 million in 2025, then surged by 35.48% to $42.0 million in 2026.
• Business Quant data shows RARE's Accounts Payables at $42.0 million in Q1 2026, $31.0 million in Q4 2025, and $40.6 million in Q3 2025.